Supported by La Roche-Posay

This program will provide an overview of AD including prevalence, severity, and disease course/progression, succinct summaries of pathophysiology and medical management, and discussion of epidermal barrier dysfunction and skin microbiome shifting associated with AD. Additional emphasis is placed on adjunctive topical skin barrier approaches that may prolong disease-free remissions. Results from a panel of dermatologists queried about adjunctive approaches to AD, using a modified-Delphi approach, are also discussed.

FACULTY
James Q. Del Rosso, DO, FAOCD, FAAD
JDR Dermatology Research/Thomas Dermatology
Las Vegas, Nevada

This webinar was previously recorded on April 22nd, 2020 and is now available on demand. Almirall has graciously supported the on-demand broadcast of this webinar.

Derm In-Review and JDD invite you to join Dermatology colleagues and as we answer resident concerns during the global coronavirus pandemic. Discussions include the date of the boards, being redeployed into other units, working on non-emergency skin conditions in clinics and many more questions submitted by your colleagues.

MODERATORS: 

• Adam Friedman, MD (Professor and Interim Chair of Dermatology, GW School of Medicine & Health Sciences)
• Misty Eleryan, MD (Chief Dermatology Resident, GW School of Medicine & Health Sciences)

PANELISTS:

• Erin Mathes, MD (Program Director, UCSF School of Medicine)
• Michael Waul, MD (Chief Resident, UCSF School of Medicine)
• Courtney Reynolds Schadt, MD (Program Director, University of Louisville School of Medicine)
• Meg Wetzel, MD (Chief Resident, University of Louisville School of Medicine)
• Sarah Robinson, MD (Associate Program Director, Tufts University School of Medicine)
• Brooke Rothstein, MD (Chief Resident, Tufts University School of Medicine)
• Holly Kerr, MD (Program Director, Henry Ford Health System)
• Angad Chadha, MD (Chief Resident, Henry Ford Health System)

SPECIAL GUESTS:

• Emily Hejazi, MD (Resident, Albert Einstein College of Medicine/Montefiore Medical Center)
• Kim Campbell (Founder, Dermatology Authority

Mindful Medicine for the Acne Patient:

•  New OTC drug and adjunctive therapy options – Hilary Baldwin, MD
•  Understanding the psychological needs of acne patients – Evan Rieder, MD

Made possible by support from La Roche-Posay.

Hilary Baldwin, MD

Hilary Baldwin is a board-certified dermatologist and medical director of the Acne Treatment & Research Center in Morristown, NJ and Brooklyn, NY.   She is a clinical associate professor of dermatologist at Rutgers Robert Wood Johnson Medical Center.  Dr. Baldwin has interests in acne, rosacea, keloidal scarring, cosmeceuticals and the skin microbiome.  She is a frequent national and international lecturer and visiting professor, and her work has been published extensively in dermatology journals. Dr. Baldwin served as a founding board member and second president of the American Acne and Rosacea Society.

Evan Rieder, MD

Dr. Evan Rieder is one of three American physicians to be dual board-certified in dermatology and psychiatry. He is a full-time faculty member of the New York University Department of Dermatology, where he practices in cosmetic and medical dermatology and hosts the Dermatology Show on Sirius XM Dr. Radio.

 

Join Michael Payette, MD, Assistant Professor of Dermatology and Associate Residency Program Director at University of Connecticut for a Next Steps in Dermatology webinar. The purpose of this webinar will be to review high-yield and representative genodermatoses from multiple categories of genetic disorders. 

1. Identify the different categories of genetic disorders
2. Describe representative features of some genodermatoses in these categories
3. Enhance their ability to recall salient features of some genodermatoses using visuals and/or mnemonics.